HRP20131142T1 - Postupci i pripravci za lijeäśenje recidiva raka - Google Patents

Postupci i pripravci za lijeäśenje recidiva raka Download PDF

Info

Publication number
HRP20131142T1
HRP20131142T1 HRP20131142AT HRP20131142T HRP20131142T1 HR P20131142 T1 HRP20131142 T1 HR P20131142T1 HR P20131142A T HRP20131142A T HR P20131142AT HR P20131142 T HRP20131142 T HR P20131142T HR P20131142 T1 HRP20131142 T1 HR P20131142T1
Authority
HR
Croatia
Prior art keywords
treatment
intended
combination
accordance
preparation
Prior art date
Application number
HRP20131142AT
Other languages
English (en)
Croatian (hr)
Inventor
Neil P. Desai
Patrick Soon-Shiong
Original Assignee
Abraxis Bioscience, Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abraxis Bioscience, Llc filed Critical Abraxis Bioscience, Llc
Publication of HRP20131142T1 publication Critical patent/HRP20131142T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5169—Proteins, e.g. albumin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/70—Nanostructure
    • Y10S977/773—Nanoparticle, i.e. structure having three dimensions of 100 nm or less
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/906—Drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Nanotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Inorganic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Optics & Photonics (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HRP20131142AT 2007-06-01 2008-06-02 Postupci i pripravci za lijeäśenje recidiva raka HRP20131142T1 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US93275007P 2007-06-01 2007-06-01
PCT/US2008/007024 WO2008150532A1 (en) 2007-06-01 2008-06-02 Methods and compositions for treating recurrent cancer

Publications (1)

Publication Number Publication Date
HRP20131142T1 true HRP20131142T1 (hr) 2014-01-03

Family

ID=39733105

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20131142AT HRP20131142T1 (hr) 2007-06-01 2008-06-02 Postupci i pripravci za lijeäśenje recidiva raka

Country Status (11)

Country Link
US (3) US8927019B2 (enExample)
EP (1) EP2155188B1 (enExample)
JP (3) JP5579057B2 (enExample)
AU (1) AU2008260447B2 (enExample)
CA (1) CA2689914C (enExample)
DK (1) DK2155188T3 (enExample)
ES (1) ES2435452T3 (enExample)
HR (1) HRP20131142T1 (enExample)
PL (1) PL2155188T3 (enExample)
PT (1) PT2155188E (enExample)
WO (1) WO2008150532A1 (enExample)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5439686A (en) * 1993-02-22 1995-08-08 Vivorx Pharmaceuticals, Inc. Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor
US8853260B2 (en) 1997-06-27 2014-10-07 Abraxis Bioscience, Llc Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
US20030199425A1 (en) * 1997-06-27 2003-10-23 Desai Neil P. Compositions and methods for treatment of hyperplasia
EP1585548B1 (en) 2002-12-09 2018-06-27 Abraxis BioScience, LLC Compositions and methods of delivery of pharmacological agents
ES2678448T3 (es) 2005-02-18 2018-08-10 Abraxis Bioscience, Llc Combinaciones y modos de administración de agentes terapéuticos y terapia combinada
US8735394B2 (en) * 2005-02-18 2014-05-27 Abraxis Bioscience, Llc Combinations and modes of administration of therapeutic agents and combination therapy
TWI417114B (zh) 2005-08-31 2013-12-01 Abraxis Bioscience Llc 具有增強穩定性之弱水溶性藥物之組合物及其製備方法
CA2672618C (en) 2006-12-14 2021-03-02 Abraxis Bioscience, Llc Breast cancer therapy based on hormone receptor status with nanoparticles comprising taxane
KR20090118999A (ko) * 2007-03-07 2009-11-18 아브락시스 바이오사이언스, 엘엘씨 항암제로서 라파마이신 및 알부민을 포함하는 나노입자
EP3326630A3 (en) * 2007-05-03 2018-08-29 Abraxis BioScience, LLC Methods and compositions for treating pulmonary hypertension
DK2155188T3 (da) 2007-06-01 2013-11-04 Abraxis Bioscience Llc Fremgangsmåder og sammensætninger til behandling af tilbagevendende kræft
CA2721153C (en) * 2008-04-10 2018-10-02 Abraxis Bioscience, Llc Compositions of hydrophobic taxane derivatives and uses thereof
CN102460167B (zh) 2009-04-15 2015-07-22 阿布拉科斯生物科学有限公司 不含朊病毒的纳米颗粒组合物和方法
NZ598801A (en) * 2009-09-18 2014-07-25 Abraxis Bioscience Llc Use of the sparc microenvironment signature in the treatment of cancer
ES2580135T3 (es) 2010-03-26 2016-08-19 Abraxis Bioscience, Llc Métodos de tratamiento de carcinoma hepatocelular
NZ628423A (en) 2010-03-29 2016-03-31 Abraxis Bioscience Llc Methods of treating cancer
AU2011232862B2 (en) 2010-03-29 2016-03-03 Abraxis Bioscience, Llc Methods of enhancing drug delivery and effectiveness of therapeutic agents
WO2011153485A2 (en) 2010-06-03 2011-12-08 Abraxis Bioscience, Llc Use of the sparc microenvironment signature in the treatment of cancer
RU2576609C2 (ru) 2010-06-04 2016-03-10 АБРАКСИС БАЙОСАЙЕНС, ЭлЭлСи Способы лечение рака поджелудочной железы
CA3063641A1 (en) 2011-04-28 2012-11-01 Abraxis Bioscience, Llc Intravascular delivery of nanoparticle compositions and uses thereof
DK2790675T3 (da) 2011-12-14 2019-09-09 Abraxis Bioscience Llc Anvendelse af polymerexcipienser til frysetørring eller frysning af partikler
DK2846809T3 (da) * 2012-05-09 2021-01-18 Cantex Pharmaceuticals Inc Behandling af myelosuppression
US9149455B2 (en) 2012-11-09 2015-10-06 Abraxis Bioscience, Llc Methods of treating melanoma
US9511046B2 (en) 2013-01-11 2016-12-06 Abraxis Bioscience, Llc Methods of treating pancreatic cancer
NZ630392A (en) 2013-03-12 2016-10-28 Abraxis Bioscience Llc Methods of treating lung cancer
WO2017161387A1 (en) * 2016-03-18 2017-09-21 Reid Christopher Brian Compositions of natural extracts and use thereof in methods for preventing or treating diseases
RU2015143490A (ru) 2013-03-14 2017-04-26 АБРАКСИС БАЙОСАЙЕНС, ЭлЭлСи Способы лечения рака мочевого пузыря
BR112017011536A2 (pt) 2014-12-02 2018-02-27 Celgene Corp terapias de combinação
WO2016133910A1 (en) 2015-02-17 2016-08-25 Cantex Pharmaceuticals, Inc. Treatment of cancers and hematopoietic stem cell disorders privileged by cxcl12-cxcr4 interaction
US10527604B1 (en) 2015-03-05 2020-01-07 Abraxis Bioscience, Llc Methods of assessing suitability of use of pharmaceutical compositions of albumin and paclitaxel
US10705070B1 (en) 2015-03-05 2020-07-07 Abraxis Bioscience, Llc Methods of assessing suitability of use of pharmaceutical compositions of albumin and poorly water soluble drug
HUE070408T2 (hu) 2015-06-29 2025-06-28 Abraxis Bioscience Llc Szirolimuszt és albumint tartalmazó nanorészecskék epitelioid sejtes tumorok kezelésében történõ alkalmazásra
AU2016323770A1 (en) * 2015-09-16 2018-03-29 Dfb Soria, Llc Delivery of drug nanoparticles and methods of use thereof
CN105412024B (zh) 2015-12-14 2018-03-30 广州帝奇医药技术有限公司 靶向疏水性抗肿瘤药物纳米制剂及其制备方法
EP3407869A1 (en) * 2016-01-27 2018-12-05 Instar Technologies A.S. Oromucosal nanofiber carriers for therapeutic treatment
AU2017219901B2 (en) 2016-02-19 2022-07-14 Nant Holdings Ip, Llc Methods of immunogenic modulation
CN110461311A (zh) * 2016-08-26 2019-11-15 奥野哲治 微细纳米化药剂及其应用
CN118948828A (zh) 2017-03-15 2024-11-15 Dfb索里亚有限责任公司 使用紫杉烷纳米颗粒治疗皮肤恶性肿瘤的局部疗法
JP7372252B2 (ja) 2018-03-16 2023-10-31 ディーエフビー ソリア リミテッド ライアビリティ カンパニー タキサンのナノ粒子を用いる子宮頸部上皮内腫瘍（ｃｉｎ）および子宮頸癌の処置のための局所療法
WO2019183146A1 (en) 2018-03-20 2019-09-26 Abraxis Bioscience, Llc Methods of treating central nervous system disorders via administration of nanoparticles of an mtor inhibitor and an albumin
EP3801069A4 (en) 2018-06-01 2022-03-16 Cornell University MULTIPLE THERAPY FOR DISEASE OR DISORDER ASSOCIATED WITH PI3K
JP2022553426A (ja) 2019-10-28 2022-12-22 アブラクシス バイオサイエンス， エルエルシー アルブミンおよびラパマイシンの医薬組成物
WO2023070023A1 (en) * 2021-10-21 2023-04-27 Faeth Therapeutics, Inc. Combination therapy for pik3ca-associated diseases or disorders

Family Cites Families (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5206018A (en) * 1978-11-03 1993-04-27 Ayerst, Mckenna & Harrison, Inc. Use of rapamycin in treatment of tumors
IT1197485B (it) * 1986-10-07 1988-11-30 Boehringer Biochemia Srl Composizioni farmaceutiche ad attivita' antineoplastica
US5540931A (en) * 1989-03-03 1996-07-30 Charles W. Hewitt Methods for inducing site-specific immunosuppression and compositions of site specific immunosuppressants
US6749868B1 (en) * 1993-02-22 2004-06-15 American Bioscience, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
US20030068362A1 (en) 1993-02-22 2003-04-10 American Bioscience, Inc. Methods and formulations for the delivery of pharmacologically active agents
US5650156A (en) * 1993-02-22 1997-07-22 Vivorx Pharmaceuticals, Inc. Methods for in vivo delivery of nutriceuticals and compositions useful therefor
US5916596A (en) 1993-02-22 1999-06-29 Vivorx Pharmaceuticals, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
US5362478A (en) 1993-03-26 1994-11-08 Vivorx Pharmaceuticals, Inc. Magnetic resonance imaging with fluorocarbons encapsulated in a cross-linked polymeric shell
US5665383A (en) * 1993-02-22 1997-09-09 Vivorx Pharmaceuticals, Inc. Methods for the preparation of immunostimulating agents for in vivo delivery
US5997904A (en) 1993-02-22 1999-12-07 American Bioscience, Inc. Total nutrient admixtures as stable multicomponent liquids or dry powders and methods for the preparation thereof
US20070117863A1 (en) 1993-02-22 2007-05-24 Desai Neil P Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
US5439686A (en) * 1993-02-22 1995-08-08 Vivorx Pharmaceuticals, Inc. Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor
US6528067B1 (en) * 1993-02-22 2003-03-04 American Bioscience, Inc. Total nutrient admixtures as stable multicomponent liquids or dry powders and methods for the preparation thereof
US6537579B1 (en) 1993-02-22 2003-03-25 American Bioscience, Inc. Compositions and methods for administration of pharmacologically active compounds
US6753006B1 (en) * 1993-02-22 2004-06-22 American Bioscience, Inc. Paclitaxel-containing formulations
US6096331A (en) * 1993-02-22 2000-08-01 Vivorx Pharmaceuticals, Inc. Methods and compositions useful for administration of chemotherapeutic agents
WO1994018954A1 (en) * 1993-02-22 1994-09-01 Vivorx Pharmaceuticals, Inc. Methods for in vivo delivery of biologics and compositions useful therefor
US5665382A (en) * 1993-02-22 1997-09-09 Vivorx Pharmaceuticals, Inc. Methods for the preparation of pharmaceutically active agents for in vivo delivery
EP1683517A1 (en) 1996-08-19 2006-07-26 American Bioscience, Inc. Methods for the production of protein particles useful for delivery of pharmacological agents
US8137684B2 (en) * 1996-10-01 2012-03-20 Abraxis Bioscience, Llc Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
PL335891A1 (en) * 1997-03-27 2000-05-22 Baker Norton Pharma Methods of and compositions for treating ovarian carcinoma
US20030199425A1 (en) 1997-06-27 2003-10-23 Desai Neil P. Compositions and methods for treatment of hyperplasia
PT1023050E (pt) 1997-06-27 2013-12-04 Abraxis Bioscience Llc Novas formulações de agentes farmacológicos, métodos para a sua preparação e métodos para a sua utilização
US8853260B2 (en) * 1997-06-27 2014-10-07 Abraxis Bioscience, Llc Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
AU777528B2 (en) 1999-04-22 2004-10-21 Abraxis Bioscience, Llc Long term administration of pharmacologically active agents
WO2000071079A2 (en) 1999-05-21 2000-11-30 American Bioscience, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
ITMI20001107A1 (it) 2000-05-18 2001-11-18 Acs Dobfar Spa Metodo per il trattamento di tumori solici mediante microparticelle di albumina incorporanti paclitaxel
EP1385551B1 (en) 2001-04-06 2008-09-03 Wyeth Antineoplastic combinations comprising cci-779 (rapamycin derivative) together with gemcitabine or fluorouracil
US20030054042A1 (en) * 2001-09-14 2003-03-20 Elaine Liversidge Stabilization of chemical compounds using nanoparticulate formulations
CA2480809A1 (en) * 2002-04-11 2003-10-23 Children's Medical Center Corporation Methods for inhibiting vascular hyperpermeability
US20040126400A1 (en) * 2002-05-03 2004-07-01 Iversen Patrick L. Delivery of therapeutic compounds via microparticles or microbubbles
MXPA05006169A (es) 2002-12-09 2006-03-30 American Biosciences Composiciones y metodos para el suministro de agentes farmacologicos.
EP1585548B1 (en) * 2002-12-09 2018-06-27 Abraxis BioScience, LLC Compositions and methods of delivery of pharmacological agents
AU2003293529A1 (en) * 2002-12-16 2004-07-29 Nitromed, Inc. Nitrosated and nitrosylated rapamycin compounds, compositions and methods of use
US20050119330A1 (en) * 2003-03-17 2005-06-02 Kao Peter N. Use of antiproliferative agents in the treatment and prevention of pulmonary proliferative vascular diseases
US20050038498A1 (en) * 2003-04-17 2005-02-17 Nanosys, Inc. Medical device applications of nanostructured surfaces
US20050152979A1 (en) * 2003-09-05 2005-07-14 Cell Therapeutics, Inc. Hydrophobic drug compositions containing reconstitution enhancer
DE10347994A1 (de) 2003-10-15 2005-06-16 Pari GmbH Spezialisten für effektive Inhalation Wässrige Aerosol-Zubereitung
MXPA06013191A (es) 2004-05-14 2007-07-24 Abraxis Bioscience Inc Metodos de tratamiento que utilizan proteinas que enlazan albumina como objetivos.
KR101341359B1 (ko) * 2004-10-01 2013-12-13 램스코르 인코포레이티드 편리하게 이식가능한 서방형 약물 조성물
WO2006053754A1 (en) 2004-11-19 2006-05-26 Novartis Ag COMBINATIONS OF ANTI-ATHEROSCLEROTIC PEPTIDES AND AN mTOR INHIBITING AGENT AND THEIR METHODS OF USE
ES2678448T3 (es) 2005-02-18 2018-08-10 Abraxis Bioscience, Llc Combinaciones y modos de administración de agentes terapéuticos y terapia combinada
US20070166388A1 (en) 2005-02-18 2007-07-19 Desai Neil P Combinations and modes of administration of therapeutic agents and combination therapy
CN101146514B (zh) 2005-02-18 2013-03-27 阿布拉西斯生物科学公司 用于整合入医疗装置的疏水性改善的药物
US8735394B2 (en) * 2005-02-18 2014-05-27 Abraxis Bioscience, Llc Combinations and modes of administration of therapeutic agents and combination therapy
BRPI0606282A2 (pt) * 2005-03-17 2009-06-09 Elan Pharma Int Ltd composições injetáveis de compostos imunossupressores em nanopartìculas
US7514549B2 (en) * 2005-04-16 2009-04-07 Michigan State University Tumor inhibition by modulating sprouty expression or activity
US20080214595A1 (en) 2005-05-16 2008-09-04 Seigo Izumo Use Of Rapamycin Derivatives For The Treatment And/Or Prevention Of Cardiovas Cular Disorders
JP5368093B2 (ja) 2005-08-31 2013-12-18 アブラクシス バイオサイエンス， エルエルシー 増大した安定性を有する難水溶性薬剤の組成物および調製の方法
TWI417114B (zh) 2005-08-31 2013-12-01 Abraxis Bioscience Llc 具有增強穩定性之弱水溶性藥物之組合物及其製備方法
CA2662140A1 (en) 2006-08-31 2008-03-06 Abraxis Bioscience, Llc Methods of inhibiting angiogenesis and treating angiogenesis-associated diseases
US20080280987A1 (en) 2006-08-31 2008-11-13 Desai Neil P Methods of inhibiting angiogenesis and treating angiogenesis-associated diseases
US20100112077A1 (en) * 2006-11-06 2010-05-06 Abraxis Bioscience, Llc Nanoparticles of paclitaxel and albumin in combination with bevacizumab against cancer
ITFI20060277A1 (it) * 2006-11-08 2008-05-09 Giuliano Giustini Sollevatore per motociclette e simili, offrente mobilita' di spostamenti omnidirezionali
CA2672618C (en) 2006-12-14 2021-03-02 Abraxis Bioscience, Llc Breast cancer therapy based on hormone receptor status with nanoparticles comprising taxane
KR20090118999A (ko) 2007-03-07 2009-11-18 아브락시스 바이오사이언스, 엘엘씨 항암제로서 라파마이신 및 알부민을 포함하는 나노입자
EP3326630A3 (en) 2007-05-03 2018-08-29 Abraxis BioScience, LLC Methods and compositions for treating pulmonary hypertension
DK2155188T3 (da) 2007-06-01 2013-11-04 Abraxis Bioscience Llc Fremgangsmåder og sammensætninger til behandling af tilbagevendende kræft
CA2721153C (en) * 2008-04-10 2018-10-02 Abraxis Bioscience, Llc Compositions of hydrophobic taxane derivatives and uses thereof
BRPI0922823A2 (pt) * 2008-12-11 2015-08-18 Abraxis Bioscience Llc Combinações e modos de administração de agentes terapêuticos e terapia de combinação
AU2010224012B2 (en) * 2009-03-13 2016-04-28 Abraxis Bioscience, Llc Combination therapy with thiocolchicine derivatives
CA2758200A1 (en) * 2009-04-10 2010-10-14 Abraxis Bioscience, Llc Nanoparticle formulations and uses thereof
CN102460167B (zh) 2009-04-15 2015-07-22 阿布拉科斯生物科学有限公司 不含朊病毒的纳米颗粒组合物和方法
NZ598588A (en) * 2009-08-25 2014-05-30 Abraxis Bioscience Llc Combination therapy with nanoparticle compositions of taxane and hedgehog inhibitors
US9775819B2 (en) * 2009-09-16 2017-10-03 R.P. Scherer Technologies, Llc Oral solid dosage form containing nanoparticles and process of formulating the same using fish gelatin
US8269348B2 (en) * 2010-02-22 2012-09-18 Texas Instruments Incorporated IC die including RDL capture pads with notch having bonding connectors or its UBM pad over the notch
ES2580135T3 (es) * 2010-03-26 2016-08-19 Abraxis Bioscience, Llc Métodos de tratamiento de carcinoma hepatocelular
AU2011232862B2 (en) * 2010-03-29 2016-03-03 Abraxis Bioscience, Llc Methods of enhancing drug delivery and effectiveness of therapeutic agents
NZ628423A (en) * 2010-03-29 2016-03-31 Abraxis Bioscience Llc Methods of treating cancer
MY188911A (en) 2010-06-02 2022-01-13 Abraxis Bioscience Llc Methods of treating bladder cancer
RU2576609C2 (ru) * 2010-06-04 2016-03-10 АБРАКСИС БАЙОСАЙЕНС, ЭлЭлСи Способы лечение рака поджелудочной железы
KR101850566B1 (ko) * 2010-06-07 2018-04-19 아브락시스 바이오사이언스, 엘엘씨 증식성 질환의 치료를 위한 조합 치료 방법
US8871256B2 (en) * 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Methods and systems for treatment of inflammatory diseases with nitric oxide
US9149455B2 (en) * 2012-11-09 2015-10-06 Abraxis Bioscience, Llc Methods of treating melanoma
US20140186447A1 (en) * 2012-12-28 2014-07-03 Abraxis Bioscience, Llc Nanoparticle compositions of albumin and paclitaxel
US9511046B2 (en) * 2013-01-11 2016-12-06 Abraxis Bioscience, Llc Methods of treating pancreatic cancer
US20140199404A1 (en) * 2013-01-11 2014-07-17 Abraxis Bioscience, Llc Method for treating cancer based on level of a nucleoside transporter
US20140199405A1 (en) * 2013-01-11 2014-07-17 Abraxis Bioscience, Llc Method for treating cancer based on mutation status of k-ras

Also Published As

Publication number Publication date
JP5579057B2 (ja) 2014-08-27
US20150079181A1 (en) 2015-03-19
US20100215751A1 (en) 2010-08-26
US8927019B2 (en) 2015-01-06
EP2155188A1 (en) 2010-02-24
JP2010529025A (ja) 2010-08-26
JP2014185186A (ja) 2014-10-02
HK1140944A1 (en) 2010-10-29
ES2435452T3 (es) 2013-12-19
CA2689914C (en) 2016-08-16
DK2155188T3 (da) 2013-11-04
WO2008150532A1 (en) 2008-12-11
US20140017316A1 (en) 2014-01-16
PL2155188T3 (pl) 2014-03-31
US20160158365A9 (en) 2016-06-09
PT2155188E (pt) 2013-12-19
AU2008260447A1 (en) 2008-12-11
JP2016172777A (ja) 2016-09-29
CA2689914A1 (en) 2008-12-11
EP2155188B1 (en) 2013-10-09
AU2008260447B2 (en) 2013-10-10

Similar Documents

Publication Publication Date Title
HRP20131142T1 (hr) Postupci i pripravci za lijeäśenje recidiva raka
JP2010529025A5 (enExample)
Limaye et al. A randomized phase II study of docetaxel with or without vandetanib in recurrent or metastatic squamous cell carcinoma of head and neck (SCCHN)
HRP20211062T1 (hr) Metode liječenja raka gušterače koje uključuju paklitaksel i gemcitabin
JP2013527232A5 (enExample)
JP2016504362A5 (enExample)
HRP20191247T1 (hr) Pertuzumab, trastuzumab, docetaksel i karboplatin za liječenje ranog stadija raka dojke
HRP20231537T1 (hr) Derivati tetrahidronaftalena i tetrahidroizokinolina kao degradatori estrogenskih receptora
WO2007139930A3 (en) Drug combinations with substituted diaryl ureas for the treatment of cancer
JP2013527233A5 (enExample)
EP2481402A3 (en) Nanoparticle comprising rapamycin and albumin as anticancer agent
HRP20150819T1 (hr) Derivati metastina i njihova uporaba
MX2009004803A (es) Nanoparticulas de paclitaxel y albumina en combinacion con bevacizumab contra el cancer.
BR112015022047A8 (pt) uso de uma composição compreendendo nanopartículas contendo um fármaco da família limo e uma albumina
JP2016513097A5 (enExample)
HRP20160609T1 (hr) Postupci liječenja hepatocelularnog karcinoma
JP2012520323A5 (enExample)
MX2020006042A (es) Metodos de tratamiento de cancer de colon usando terapia combinada de inhibidor del objetivo mamifero de la rapamicina (mtor) en nanoparticulas.
RU2010151602A (ru) Комбинированная терапия с помощью рм00104 и другого противоопухолевого средства
HRP20230523T1 (hr) Antitumorski agens i sredstvo za poboljšavanje antitumorskog efekta
BR112012003907A2 (pt) composições farmacêuticas para prevenção ou tratamento da osteoporose, a ser adminstrada uma vez por mês
HRP20191248T1 (hr) Kombinirana terapija za liječenje karcinoma jajnika
ATE506955T1 (de) Zusammensetzungen zur verringerung der toxizität von cisplatin, carboplatin und oxaliplatin
HRP20210010T1 (hr) Injekcijske farmaceutske formulacije lefamulina
JP2008533021A5 (enExample)